NEW YORK ( TheStreet) -- Shares of Pharmaceutical Product Development (Nasdaq: PPDI) have taken a tremendous swing upward. The stock is trading at $32.22 as of 10:06 a.m. ET, 25.6% above Friday's closing price of $25.66. Volume is at 5.7 million, 3.7 times the daily average of 1.5 million. Pharmaceutical Product Development has a market cap of $3 billion and is part of the health care sector and health services industry. Shares are down 5.5% year to date as of the close of trading on Friday. Pharmaceutical Product Development, Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. It operates in two segments, Clinical Development Services and Laboratory Services. The company has a P/E ratio of 41.6, above the average health services industry P/E ratio of 18.2 and above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pharmaceutical Product Development as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Pharmaceutical Product Development Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
More from Markets
This Flat Market Action Is Favorable for Stock Pickers
There still is no compelling reason to bet on a major market correction at this time.
Disney's Price Target Is Raised at Bernstein on Strong Streaming Numbers
Walt Disney's price target is raised to $137 from $131 by analysts at Bernstein and its market perform rating affirmed.
China and the Markets, Trading Target, Eye on Cornerstone OnDemand: Market Recon
Clearly, Wednesday was a day of broad portfolio distribution. Not, however, the end of the world.
The Only 2 Things You Need to Know About This Market
The biggest consequence of the focus on China trade is that it is preventing corrective action from developing.
TD Ameritrade, Apple, Macy's, Tesla, Tiffany - 5 Things You Must Know Thursday
U.S. stock futures point to a mixed start for Wall Street as investors continue to question the chances of a near-term trade pact between Washington and Beijing; Donald Trump hints he may exempt Apple from new tariffs on Chinese imports; Tesla to unveil its electric pickup truck on Thursday.